Showing posts with label autoimmune disease. Show all posts
Showing posts with label autoimmune disease. Show all posts

Wednesday, August 19, 2015

%Microbes in our intestines can trigger #autoimmune uveitis, and a new study found microbes produce #proteins allowing harmful #immunecells to enter our eyes.% - http://clapway.com/2015/08/19/autoimmune-blindness-gut-microbes-101

Autoimmune uveitis is among the leading causes of blindness. There exist microbes that dwell naturally in our intestines that can be trigger to this disease, and a new study has found that some such microbes produce proteins that candor to harmfully maladjusted immune cells’ entering our eyes.


AUTOIMMUNE DISEASE ATTACKS EYES


This notion of intestinal microbes promoting autoimmune uveitis “has been there in the back of our minds,” comments ocular immunologist Andrew Taylor of the Boston University School of Medicine, a scientific bystander. “This is the first time that it’s been shown that gut flora seems to be part of the process.”


In fact, roughly 400,000 people presently in the States have autoimmune uveitis, a disease that sets the body’s means of controlling the immune system, T cells, on a mission to invade the eye and damage its middle layer. T cells are triggered by a special molecule called antigens, and when eye proteins are misidentified as antigens, T cells go haywire and attack. This isn’t an exceptional condition; healthy people possess the same T cells, it’s just that they don’t usually attack the eyes en masse. In order for T cells to attack at all they must first be activated by their corresponding antigen. It’s rare for antigens associated with autoimmune uveitis to leave the eye, so the question at hand is how on Earth are the wrong T cells stimulated the wrong way?


GUT MICROBES TO BLAME


The new study’s immunologist Rachel Caspi of the National Eye Institute in Bethesda, Maryland, along with her colleagues, performed some genetic engineering on mice to trigger their T cells in the wrong way described above. The critters developed symptoms just as they were weaned. However, the study found that giving the mice four antibiotics capable of killing most of their gut microbes actually delayed the onset and reduced the severity of the disease. This effect was also noticed in germ-free mice, referred to as such because of their lack of gut bacteria.


EXTENSIVE T CELL TESTING


In order to know if gut microbes were actually stimulating the wrong T cells, Caspi and crew mixed intestinal contents of diseased mice to T cell cultures. This lovely cocktail activated the T cells, which means they had become the wrong kind, ready to infect. Caspi’s team suspected a specific protein intestinal microbes release of triggering T cells, so they injected a protein-destroying enzyme to the intestinal cocktail. Afterwards the T cell had a sluggish response to stimuli, which lends weight to the notion of them responding to a protein. Separately, scientists injected T cells from genetically altered mice into control mice not susceptible to autoimmune uveitis, the hypothesis being that T cells unexposed to intestinal material cannot cause uveitis. However, 86% of the mice developed the disease unless they had not received the major dose of T cells formerly exposed to diseased intestinal contents, reported researchers in Immunity, yesterday.


This means that a specific group of bacteria natural to the intestines produces proteins akin to those found in the eye, activating T cells present in the intestines. “We can prove that activation is occurring in the gut,” Caspi announced. Post-activation, these renegade T cells are then presumed to journey up to the eyes, where they force their way in and wreak a blinding havoc.

“It’s a very rigorous approach, and it really adds to our knowledge” regarding how autoimmune uveitis gets its start, remarked ocular immunologist Russell Read of the University of Alabama, Birmingham, another scientific spectator.


PRELIMINARY CONCLUSIONS & NEW QUESTIONS


So far this is solid scientific progress, but the next question to answer, according to immunologist James Rosenbaum of the Oregon Health & Science University in Portland, is why only some (and not all) of us develop autoimmune reactions in our retinas. He goes on to suggest that perhaps only some humans have the bacteria necessary to stimulate T cells, or that a genetic predisposition may be involved.


Caspi and crew don’t want to raise false hopes of popping some antibiotic to cure autoimmune uveitis, but by cataloging gut mimesis of ocular proteins in conjunction with trigger-happy bacteria, researchers may one day procure new methods to treat or prevent this mysterious disease.


story originally covered by Mitch Leslie of Science Magazine



 


ENJOY HEALTHY EYES WITH LIFELIGHT; SUNLIGHT INDOORS


https://youtu.be/OkdNaE0dwk0



Autoimmune Disease Behind Blindness Caused By Gut Microbes

Friday, June 26, 2015

Drug Typically Used for Arthritis Possibly Treats Vitiligo Too - http://clapway.com/2015/06/26/drug-typically-used-for-arthritis-possibly-treats-vitiligo-too323/

A recent experiment which tested a middle-aged woman suffering from progressive vitiligo, was shown to have resulted in most of her patched skin turning back to its original color. This was all thanks to an oral drug, tofacitinib, usually meant for treating severe cases of rheumatoid arthritis.


About the drug in question for treating vitiligo


The drug in question, tofacitinib, “belongs to a family of drugs known as Janus kinase (JAK) inhibitors that have been approved… by the US Food and Drug Association (FDA)” according to recent reports. This drug is typically prescribed to those who are diagnosed with moderate to severe rheumatoid arthritis. Additionally, when it comes to degenerative diseases such as vitiligo, tofacitinib has also been proven to treat alopecia, a condition which results in hair loss.


The experiment conducted for testing vitiligo


One 53-year-old woman was tested to see if her progressive vitiligo can be treated with the use of the arthritis drug, tofacitinib. The experiment was conducted by having her take 5mg of the oral drug once a day, the dosageeventually being increased by 5mg about a month later. Taking a dose of approximately 10mg of tofacitinib proved show success after two months as the woman’s white patches were showing partial repigmentation. According to researchers of the study, “After 5 months, the white patches she had been most concerned with on her face and hands were nearly all gone. Only a few white spots remained on other parts of her body”. It appears with this experiment/trial, that this discovery is definitely, and truly a breakthrough, when it comes to an autoimmune disease, such as vitiligo, finally having a potential medication to help treat the horrendous depigmentation.


Any long-term and adverse effects at the moment?


During, and after, the experiment, there appeared to be no long-term, adverse effects when the woman was on the tofacitinib trial, for her vitiligo. However, because only one woman was used during the trail there would need to be a lot more people recruited for further findings. This is to make sure the findings are more concrete and is safe, as well as truly an appropriate treatment for vitiligo, for sufferers of the autoimmune disease to benefit from.


For more information on this experiment/trial, please go to JAMA Network.



 


 


Want to cut down on snacking, fingernail-biting, or any other bad habits? Try the Pavlok shock bracelet.




Drug Typically Used for Arthritis Possibly Treats Vitiligo Too